FDA updates cover substantial evidence, gene therapy and AI-enabled early-phase clinical trials

Aug 26, 2026 · Issue 4 · 2 sources, 2 articles

A summary of FDA updates lists the substantial evidence requirement, gene therapy development and AI-enabled early-phase clinical trials among the topics (26 August 2026).

Who is affected and how

pharmaceuticals

The FDA's position on the use of AI in early-phase trials should be taken into account in development plans.

Sources

• Key FDA Updates: Substantial Evidence, Gene Therapy Development and AI-Enabled Early-Phase Clinical Trialsmcguirewoods · Aug 26, 2026
• Uses of AI Tools in Clinical Trials: Key Applicationsclinilaunchresearch.in · Aug 28, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.